Penumbra, Inc. (FRA:0P8)

Market Cap	11.28B +15.1%
Revenue (ttm)	1.14B +14.6%
Net Income	139.80M +374.8%
EPS	3.53 +367.3%
Shares Out	n/a
PE Ratio	80.69
Forward PE	71.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	288.80
Previous Close	288.60
Day's Range	287.10 - 288.80
52-Week Range	193.10 - 306.40
Beta	n/a
RSI	50.74
Earnings Date	Feb 23, 2026

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2004
• Employees: 4,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0P8

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Financial numbers in USD